A large fraction of patients with diabetes mellitus require insulin treatment to control glucose metabolism; however, this treatment brings risks of hypoglycaemia and provides suboptimal metabolic control. Transplantation of stem cell-derived pancreatic islet cells could be an ideal solution, which is approaching clinical translation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification
Nature Cell Biology Open Access 15 May 2023
-
Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin
Cell Death & Disease Open Access 25 July 2022
-
Tissue Engineering Strategies for Improving Beta Cell Transplantation Outcome
Current Transplantation Reports Open Access 25 June 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America 3rd ed (NIH, 2018).
Augsornworawat, P., Maxwell, K. G., Velazco-Cruz, L. & Millman, J. R. Single-cell transcriptome profiling reveals beta cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067 (2020).
Ricordi, C. et al. National Institutes of Health-sponsored clinical islet transplantation consortium phase 3 trial: manufacture of a complex cellular product at eight processing facilities. Diabetes 65, 3418–3428 (2016).
Lablanche, S. et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 527–537 (2018).
Ricordi, C. et al. Transplanting islet cells can fix brittle diabetes. Why isn’t it available in the U.S.? CellR4 7, e2768 (2019).
D’Amour, K. A. et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat. Biotechnol. 24, 1392–1401 (2006).
Pagliuca, F. W. et al. Generation of functional human pancreatic beta cells in vitro. Cell 159, 428–439 (2014).
Velazco-Cruz, L. et al. Acquisition of dynamic function in human stem cell-derived beta cells. Stem Cell Reports 12, 351–365 (2019).
Agulnick, A. D. et al. Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo. Stem Cells Transl Med. 4, 1214–1222 (2015).
Millman, J. R. et al. Generation of stem cell-derived beta-cells from patients with type 1 diabetes. Nat. Commun. 7, 11463 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lanzoni, G., Ricordi, C. Transplantation of stem cell-derived pancreatic islet cells. Nat Rev Endocrinol 17, 7–8 (2021). https://doi.org/10.1038/s41574-020-00430-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-020-00430-9
This article is cited by
-
Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification
Nature Cell Biology (2023)
-
Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin
Cell Death & Disease (2022)
-
Recapitulating pancreatic cell–cell interactions through bioengineering approaches: the momentous role of non-epithelial cells for diabetes cell therapy
Cellular and Molecular Life Sciences (2021)
-
Tissue Engineering Strategies for Improving Beta Cell Transplantation Outcome
Current Transplantation Reports (2021)